Journal
EUROPEAN HEART JOURNAL
Volume 33, Issue 18, Pages 2360-2369Publisher
OXFORD UNIV PRESS
DOI: 10.1093/eurheartj/ehr389
Keywords
Apelin; Cardiac fibroblast; Fibrosis; Myocardial remodelling
Categories
Funding
- Institut National de la Sante et de la Recherche Medicale
- Fondation de France
- Region Midi-Pyrenees
- Association Francaise d'Etude et de Recherche sur l'Obesite (AFERO)
- Universite Paul Sabatier
- Prostate UK [G2009/28]
- Prostate Cancer Charity [110854]
Ask authors/readers for more resources
Activation of cardiac fibroblasts and their differentiation into myofibroblasts is a key event in the progression of cardiac fibrosis that leads to end-stage heart failure. Apelin, an adipocyte-derived factor, exhibits a number of cardioprotective properties; however, whether apelin is involved in cardiac fibroblast activation and myofibroblast formation remains unknown. The aim of this study was to determine the effects of apelin in activated cardiac fibroblasts, the potential related mechanisms and impact on cardiac fibrotic remodelling process. In vitro experiments were performed in mouse cardiac fibroblasts obtained from normal and pressure-overload hearts. Pretreatment of naive cardiac fibroblasts with apelin (1100 nM) inhibited Transforming growth factor- (TGF-)-mediated expression of the myofibroblast marker -smooth muscle actin (-SMA) and collagen production. Furthermore, apelin decreased the spontaneous collagen production in cardiac fibroblasts isolated from hearts after aortic banding. Knockdown strategy and pharmacological inhibition revealed that prevention of collagen accumulation by apelin was mediated by a reduction in sphingosine kinase 1 (SphK1) activity. In vivo studies using the aortic banding model indicated that pretreatment with apelin attenuated the development of myocardial fibrotic remodelling and inhibited cardiac SphK1 activity and -SMA expression. Moreover, administration of apelin 2 weeks after aortic banding prevented cardiac remodelling by inhibiting myocyte hypertrophy, cardiac fibrosis, and ventricular dysfunction. Our data provide the first evidence that apelin inhibits TGF--stimulated activation of cardiac fibroblasts through a SphK1-dependent mechanism. We also demonstrated that the administration of apelin during the phase of reactive fibrosis prevents structural remodelling of the myocardium and ventricular dysfunction. These findings may have important implications for designing future therapies for myocardial performance during fibrotic remodelling, affecting the clinical management of patients with progressive heart failure.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available